Hepatorenal Syndrome Clinical Trial
Official title:
Use of Novel Plasma and Urinary Biomarkers to Predict the Development of Hepatorenal Syndrome in Cirrhotic Patients
This study investigated the use of novel plasma and urinary biomarkers to predicte the development of hepatorenal syndrome in patients with advanced cirrhosis. The biomarkers investigated include plasma cystatin C, plasma NGAL, plasma NAG, plasma IL-18, plasma ADMA, plasma BTP, urinary KIM-1 and urinary LFABP. These biomarkers will be checked in advanced cirrhotic patients who have or have not developed hepatorenal syndrome and compared between the two groups. These biomarkers will also be correlated with the occurence of hepatorenal syndrome.
This study investigated the use of novel plasma and urinary biomarkers to predicte the development of hepatorenal syndrome in patients with advanced cirrhosis. The biomarkers tested include plasma cystatin C, plasma NGAL, plasma NAG, plasma IL-18, plasma ADMA, plasma BTP, urinary KIM-1 and urinary LFABP. These biomarkers will be checked in advanced cirrhotic patients who have or have not developed hepatorenal syndrome and compared between the two groups. These biomarkers will also be correlated with the occurence of hepatorenal syndrome. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00370253 -
Noradrenalin vs Terlipressin in Hepatorenal Syndrome
|
Phase 3 | |
Completed |
NCT00359853 -
Norfloxacin In The Primary Prophylaxis Of Spontaneous Bacterial Peritonitis
|
Phase 4 | |
Completed |
NCT01436500 -
Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients
|
Phase 2 | |
Completed |
NCT01143246 -
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
|
Phase 3 | |
Recruiting |
NCT05346393 -
HRS-AKI Treatment With TIPS in Patients With Cirrhosis
|
N/A | |
Terminated |
NCT00734136 -
Role Of Angiogenic Factors In The Development Of Hepatorenal Syndrome
|
N/A | |
Terminated |
NCT00742339 -
Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome
|
Phase 2/Phase 3 | |
Recruiting |
NCT06095440 -
A Retrospective Analysis of Outcomes in Patients With Hepatorenal Syndrome at Methodist Dallas Medical Center
|
||
Completed |
NCT02097784 -
Interest of the Echocardiography in the Management of Cirrhotic Patients With Acute Kidney Injury
|
N/A | |
Recruiting |
NCT04898010 -
The Selective Cytopheretic Device (SCD) for Acute Kidney Injury (AKI) and Hepatorenal Syndrome (HRS) Type I
|
N/A | |
Recruiting |
NCT05875948 -
Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome
|
Phase 2 | |
Completed |
NCT04416282 -
Efficacy of Early Terlipressin Plus Albumin Therapy in Comparison to Standard Treatment for HRS-AKI in Acute-on-chronic Liver Failure.
|
N/A | |
Recruiting |
NCT02049125 -
Study of Accuracy of NGAL, a Renal Injury Biomarker, in Patients With Cirrhosis
|
N/A | |
Completed |
NCT00764049 -
Single Pass Albumin Dialysis in Patients With Cirrhosis
|
Phase 1/Phase 2 | |
Completed |
NCT00089570 -
Study of Terlipressin Versus Placebo to Treat Hepatorenal Syndrome Type 1
|
Phase 3 | |
Withdrawn |
NCT01587222 -
Midodrine, Octreotide and Albumin: Impact on Renal Function of Patients With Liver Cirrhosis and Renal Failure
|
Phase 2 | |
Recruiting |
NCT02489864 -
The Effect of Terlipressin in the Prevention of Type 2 Hepatorenal Syndrome by Improving Mean Arterial Pressure
|
Phase 4 | |
Completed |
NCT02770716 -
Study To Confirm Efficacy and Safety of Terlipressin in Hepatorenal Syndrome (HRS) Type 1
|
Phase 3 | |
Completed |
NCT05387811 -
International Registry of Acute Kidney Injury in Cirrhosis: The GLOBAL AKI Project
|
||
Withdrawn |
NCT04048707 -
Angiotensin 2 for Hepatorenal Syndrome
|
Phase 2 |